Adenosine reuptake inhibitor

An adenosine reuptake inhibitor (AdoRI) is a type of drug which acts as a reuptake inhibitor for the purine nucleoside and neurotransmitter adenosine by blocking the action of one or more of the equilibrative nucleoside transporters (ENTs).^[1]^[2]^[3] This in turn leads to increased extracellular concentrations of adenosine and therefore an increase in adenosinergic neurotransmission.

^ SenGupta DJ, Unadkat JD (2004). "Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep". Biochem Pharmacol. 67 (3): 453–458. doi:10.1016/j.bcp.2003.09.018. PMID 15037197.
^ Endres CJ, Sengupta DJ, Unadkat JD (2004). "Mutation of leucine-92 selectively reduces the apparent affinity of inosine, guanosine, NBMPR [S6-(4-nitrobenzyl)-mercaptopurine riboside] and dilazep for the human equilibrative nucleoside transporter, hENT1". Biochem J. 380 (1): 131–137. doi:10.1042/BJ20031880. PMC 1224139. PMID 14759222.
^ Chaudary N, Naydenova Z, Shuralyova I, Coe IR (2004). "The adenosine transporter, mENT1, is a target for adenosine receptor signaling and protein kinase Cepsilon in hypoxic and pharmacological preconditioning in the mouse cardiomyocyte cell line, HL-1". J Pharmacol Exp Ther. 310 (3): 1190–1198. doi:10.1124/jpet.104.067157. PMID 15131243. S2CID 21804556.